117 related articles for article (PubMed ID: 38739434)
1. IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion.
Li J; Clark R; Slaga D; Avery K; Liu K; Schubbert S; Varma R; Chiang E; Totpal K; Bernett MJ; Holder PG; Junttila TT
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38739434
[TBL] [Abstract][Full Text] [Related]
2. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
[TBL] [Abstract][Full Text] [Related]
3. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
4. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
[TBL] [Abstract][Full Text] [Related]
5. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.
Lu D; Yadav R; Holder P; Chiang E; Sanjabi S; Poon V; Bernett M; Varma R; Liu K; Leung I; Bogaert L; Desjarlais J; Shivva V; Hosseini I; Ramanujan S
Eur J Pharm Sci; 2023 Jul; 186():106450. PubMed ID: 37084985
[TBL] [Abstract][Full Text] [Related]
6. Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines
Shehata HM; Dogra P; Gierke S; Holder P; Sanjabi S
Front Immunol; 2024; 15():1341804. PubMed ID: 38515757
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
Kamakura D; Asano R; Kawai H; Yasunaga M
Cancer Immunol Immunother; 2021 Jan; 70(1):177-188. PubMed ID: 32666260
[TBL] [Abstract][Full Text] [Related]
8. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Li J; Stagg NJ; Johnston J; Harris MJ; Menzies SA; DiCara D; Clark V; Hristopoulos M; Cook R; Slaga D; Nakamura R; McCarty L; Sukumaran S; Luis E; Ye Z; Wu TD; Sumiyoshi T; Danilenko D; Lee GY; Totpal K; Ellerman D; Hötzel I; James JR; Junttila TT
Cancer Cell; 2017 Mar; 31(3):383-395. PubMed ID: 28262555
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.
Yadav R; Sukumaran S; Zabka TS; Li J; Oldendorp A; Morrow G; Reyes A; Cheu M; Li J; Wallin JJ; Tsai S; Sun L; Wang P; Ellerman D; Spiess C; Polson A; Stefanich EG; Kamath AV; Ovacik MA
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631556
[TBL] [Abstract][Full Text] [Related]
10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
11. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K; Zuch de Zafra CL; Schutt LK; Clark V; Zhong F; Hristopoulos M; Clark R; Li J; Mathieu M; Chen X; Johnston J; Low J; Ybarra R; Slaga D; Yang J; Ovacik M; Dybdal NO; Totpal K; Junttila MR; Ellerman D; Lee G; Dennis MS; Prell R; Junttila TT
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271166
[TBL] [Abstract][Full Text] [Related]
12. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4
Awad RM; De Vlaeminck Y; Meeus F; Ertveldt T; Zeven K; Ceuppens H; Goyvaerts C; Verdonck M; Salguero G; Raes G; Devoogdt N; Breckpot K
Sci Rep; 2023 Nov; 13(1):18995. PubMed ID: 37923822
[TBL] [Abstract][Full Text] [Related]
13. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
15. Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.
Xie F; Zhang L; Shi S; Zheng A; Di J; Jin S; Miao X; Wu F; Chen X; Zhang Y; Wei X; Xu Y
MAbs; 2022; 14(1):2115205. PubMed ID: 36041060
[TBL] [Abstract][Full Text] [Related]
16. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
17. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
18. Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P; Sun LL; Clark R; Hristopoulos M; Chiu CPC; Dillon M; Lin W; Lo AA; Chalsani S; Das Thakur M; Zimmerman Savill KM; Rougé L; Lupardus P; Piskol R; Husain B; Ellerman D; Shivva V; Leong SR; Ovacik M; Totpal K; Wu Y; Spiess C; Lee G; Leipold DD; Polson AG
Mol Cancer Ther; 2022 Jun; 21(6):974-985. PubMed ID: 35364611
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT; Li J; Johnston J; Hristopoulos M; Clark R; Ellerman D; Wang BE; Li Y; Mathieu M; Li G; Young J; Luis E; Lewis Phillips G; Stefanich E; Spiess C; Polson A; Irving B; Scheer JM; Junttila MR; Dennis MS; Kelley R; Totpal K; Ebens A
Cancer Res; 2014 Oct; 74(19):5561-71. PubMed ID: 25228655
[TBL] [Abstract][Full Text] [Related]
20. Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Lo AA; Johnston J; Li J; Mandikian D; Hristopoulos M; Clark R; Nickles D; Liang WC; Hötzel K; Dunlap D; Pham T; Cai H; Ovacik M; Bravo-Perez D; Mai E; Slaga D; Ellerman D; Ziai J; Totpal K; Lee G; Boswell CA; Payandeh J; Wu Y; Junttila TT
Mol Cancer Ther; 2021 Apr; 20(4):716-725. PubMed ID: 33536191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
